Jpmorgan Chase & CO Adagio Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,888 shares of ADGI stock, worth $112,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,888

Previous 44,017 23.01%

Holding current value

$112,169

Previous $145,000 22.76%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	N/A	-10,129 Reduced 23.01%	33,888 $112,000
Q1 2024 May 10, 2024	BUY	N/A	30,846 Added 234.2%	44,017 $145,000
Q4 2023 Feb 12, 2024	SELL	N/A	-7,616 Reduced 36.64%	13,171 $43,000
Q3 2023 Nov 14, 2023	BUY	N/A	17,320 Added 499.57%	20,787 $68,000
Q2 2023 Aug 11, 2023	SELL	N/A	-322,120 Reduced 98.94%	3,467 $11,000
Q1 2023 May 18, 2023	BUY	N/A	39,325 Added 13.74%	325,587 $1.08 Million
Q1 2023 May 11, 2023	SELL	N/A	-38,571 Reduced 11.87%	286,262 $947,000
Q4 2022 Feb 13, 2023	SELL	$3.08 - $4.05 $147,279 - $193,662	-47,818 Reduced 12.83%	324,833 $487,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $58,206 - $94,658	19,598 Added 5.55%	372,651 $1.17 Million
Q2 2022 Aug 11, 2022	SELL	$2.54 - $4.52 $33,881 - $60,292	-13,339 Reduced 3.64%	353,053 $1.16 Million
Q1 2022 May 11, 2022	BUY	$3.81 - $10.77 $1.35 Million - $3.81 Million	353,341 Added 2707.39%	366,392 $1.67 Million
Q4 2021 Feb 10, 2022	BUY	$6.35 - $47.04 $33,045 - $244,796	5,204 Added 66.32%	13,051 $94,000
Q3 2021 Nov 12, 2021	BUY	$20.88 - $56.08 $163,845 - $440,059	7,847 New	7,847 $332,000

Others Institutions Holding ADGI

# of Institutions

Shares Held

67.3M

Call Options Held

700K

Put Options Held

600

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Adagio Therapeutics, Inc. Transaction History